News

OTR3 announces first patient enrollment in its pivotal study “MATRISCAR”, a double blind placebo-controlled study aimed at demonstrating the effects of CACIPLIQ20 on Post-surgical Scars

OTR3 announces first patient enrolled in a Phase I study of OTR4132-MD in Acute Ischemic Stroke (AIS).

OTR3 announces first patient enrolled in a post market clinical follow up on Cacipliq 20®..

OTR3 starts a post market clinical follow up on Cacipliq 20®.

OTR3 receives approval from ANSM to start new clinical trial with the application of a RGTA® product in ischemic stroke.

OTR3 receives a state guaranteed loan amounting to € 0.5 m.

OTR3 appoints new management teams as the company planned to launch a second generation of RGTA® products.